Longeveron (NASDAQ:LGVN) Upgraded at Wall Street Zen

Longeveron (NASDAQ:LGVN) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other equities research analysts have also recently issued research reports about the company. Maxim Group cut Longeveron from a “buy” rating to a “hold” rating in a research note on Monday, May 11th. HC Wainwright decreased their target price on Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, May 4th. Finally, Weiss Ratings cut Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, June 5th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.50.

Longeveron Trading Up 1.5%

Shares of NASDAQ LGVN opened at $0.78 on Friday. The stock has a market cap of $24.38 million, a price-to-earnings ratio of -0.69 and a beta of -0.35. The business has a 50 day simple moving average of $0.89 and a 200 day simple moving average of $0.73. Longeveron has a 52 week low of $0.48 and a 52 week high of $1.80. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.88 and a current ratio of 3.88.

Longeveron (NASDAQ:LGVN) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.33 million. Longeveron had a negative return on equity of 202.41% and a negative net margin of 1,844.49%. On average, research analysts predict that Longeveron will post -0.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd purchased a new position in shares of Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron as of its most recent SEC filing. 10.01% of the stock is currently owned by institutional investors and hedge funds.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.